

## **Purified Inactivated Zika Vaccine Candidates Afford Protection against Lethal Challenge in Mice**


Whitney R. Baldwin<sup>1,2†</sup>, Jill A. Livengood<sup>1†\*</sup>, Holli A. Giebler<sup>1,2</sup>, Janae L. Stovall<sup>2</sup>, Karen L. Boroughs<sup>2</sup>, Stephanie Sonnberg<sup>1</sup>, Kelly J. Bohning<sup>1</sup>, Elizabeth A. Dietrich<sup>2</sup>, Yee Tsuey Ong<sup>2</sup>, Hoang K. Danh<sup>1</sup>, Hetal K. Patel<sup>1</sup>, Claire Y.H. Huang<sup>2\*</sup>, Hansi J. Dean<sup>1</sup>

<sup>1</sup> Takeda Vaccines Inc, Cambridge, MA, USA

<sup>2</sup> Arboviral Diseases Branch, Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, Fort Collins, Colorado, USA

†Contributed equally.

\*Correspondence and request for materials should be addressed to J.A.L. (jill.livengood@takeda.com) and C.Y-H.H. (yxh0@cdc.gov)




**d.**


Antigen input/well	Antigen dilution points (10-fold)				
	1	2	3	4	5
ZIKV ( $\log_{10} \text{TCID}_{50}$ )	nd	6.83	5.83	4.83	3.83
PIZV-e ( $\mu\text{g}$ )	nd	0.60	0.060	0.0060	nd
sE ( $\mu\text{g}$ )	5.6	0.56	0.056	0.0056	nd

**Supplementary Fig. S1a-d. Sandwich ELISA.** Serially diluted antigens (10-fold) were captured by EDE C8 or EDE C10, and detected by either 4G2 or 1176-56. (a) EDE C8/4G2 (b) EDE C10/4G2 (c) EDE C10/1176-56. (d) Antigen input amount for each dilution. Positive cutoff (shaded in grey) was set at OD405 > negative control OD average (from 6 replicates) +6xSD. Shaded areas indicate an antigen input amount that resulted in a positive result for panels a and b only. For panel C, only sE was detectable by 1176-56.

a.



b.



**Supplementary Fig. S2a-b. Average weight of AG129 test groups post-challenge.** (a) immunogenicity and efficacy study (b) passive immunization study. Average weights are represented as a percentage of starting weight.